Tag:

Generic drugs

Latest Headlines

Latest Headlines

Medicaid would have saved $1.4B with discounts for generics: Report

Sen. Bernie Sanders (I-VT) and Rep. Elijah Cummings (D-MD) can add some ammo to their drug price-fighting arsenal, as a new report shows that Medicaid could have saved $1.4 billion over the last 10 years if companies were forced to offer discounts if prices for top-selling generic drugs surpassed the rate of inflation.

Japan poised to put 70% price lid on biosimilars, cap generics at 50% of reference drug

Japan is considering capping the price of biosimilars at 70% of the reference drug, while lowering the price cap on generics from 60% to 50% of the price for the drugs they copy. 

Shire's bid to block Lialda copies hits another snag

Shire shares slumped Thursday after a U.S. Appeals Court denied its latest attempt to fend off generic versions of its ulcerative colitis treatment Lialda. The drug is one of Shire's top sellers--and the case is one of the first reviewed under a U.S. Supreme Court patent-law ruling.

Trans-Pacific Partnership push waits on cue from Obama's India visit

SINGAPORE-- India is not a member of the 12-nation Trans-Pacific Partnership, but its intellectual property rules governing pharmaceutical patents lie at the core of a dispute ginning up this year to reach a final agreement. India's resistance to relaxing its rules has been a model for the emerging-market members of the TPP to seek similar compulsory licensing arrangements for generic drugs.

FDA to Mallinckrodt: Generic Concerta doesn't measure up to J&J's brand

The FDA's new due diligence on generic drugs now has one victim: Mallinckrodt, which makes a knockoff version of Johnson & Johnson's ADHD drug Concerta. The Dublin-based drugmaker says the FDA is questioning whether its generic actually measures up to the brand.

Alabama Supreme Court redux: Pfizer can be sued for generic Reglan harms

The Alabama Supreme Court won't back away from a controversial ruling against Pfizer, in a liability case closely watched by the rest of the pharma industry.

Generics snafus give Big Pharma a windfall, but cost U.S. patients billions

FDA actions against India's Ranbaxy Laboratories ostensibly are keeping U.S. consumers safer, but much poorer. The plant bans have also shined a spotlight on how complex drug laws in the U.S. can work against consumers' best interests.

FDA looks at effectiveness of generic blood pressure drugs

Generic drugs underpin the U.S. prescription drug market, making up 80% of the prescriptions written in the country and saving payers billions of dollars annually. But there have always been questions about whether some generics are as effective as the drugs they copy, and the FDA last year kicked off a program to find out.

Big Pharma accused of hatching 'satanic plot' in South Africa

South Africa's Minister of Health, Aaron Motsoaledi, lashed out on Friday at a report that Big Pharma is funding a PR campaign aimed at opposing new patent provisions favoring generic drugs, calling it "a conspiracy of satanic magnitude" that would lead to "genocide."

Thank pharma's patent cliff for helping to depress health-spending growth

U.S. healthcare spending is on the rise. But for the fourth year in a row, in 2012, those increases were comparatively modest, a new report says. As to whether it's the Affordable Care Act or lingering effects of the recession that's principally responsible for the slower spending growth, officials are divided. One thing they agree on: Falling drug prices had something to do with it.